## Amendments to the Claims

- 1. (Currently Amended) A pharmaceutical composition comprising an acidic aqueous solution comprising the The insulin analog A0<sup>Arg</sup>A21<sup>Gly</sup>B31<sup>Arg</sup>B32<sup>Arg</sup>-human insulin, wherein the insulin analog is not covalently bound to a fatty acid.
  - 2. (Canceled)
  - 3. (Canceled)
- 4. (Currently Amended) The <u>pharmaceutical</u> composition of claim <u>1</u> 3, further comprising one or more pharmaceutically acceptable excipients.
- 5. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claims 2-4</u>, further comprising a divalent metal cation.
- 6. (Currently Amended) The <u>pharmaceutical</u> composition of claim 5, wherein the divalent metal cation is zinc.
- 7. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claims 2-6</u>, further comprising a phenolic preservative.
- 8. (Currently Amended) The <u>pharmaceutical</u> composition of <u>claim 1</u> any one of <u>claim 2-6</u>, further comprising an isotonicity agent.
- 9. (Currently Amended) A method of treating hyperglycemia, the method comprising administering the <u>pharmaceutical composition</u> insulin analog of claim 1 to a subject in an amount sufficient to regulate blood glucose concentration in the subject.

- 10. (Currently Amended) A method of treating hyperglycemia, the method comprising administering the <u>pharmaceutical</u> composition of any one of claims <u>4, 5, 6, 7, 8 or</u> <u>9 2-8</u> to a subject in an amount sufficient to regulate blood glucose concentration in the subject.
- 11. (Currently Amended) The method of claim 9 or 10, wherein the subject is treated for diabetes mellitus.
  - 12. (Canceled)

    13. (Canceled)

    14. (Canceled)

    15. (Canceled)

    16. (Canceled)

    17. (Canceled)

    18. (Canceled)

    19. (Canceled)

    20. (Canceled)

21. (Canceled)

22. (New) The method of claim 10, wherein the subject is treated for diabetes mellitus.